Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own47.10% Shs Outstand14.75M Perf Week16.22%
Market Cap56.16M Forward P/E- EPS next Y- Insider Trans4.13% Shs Float7.82M Perf Month151.66%
Income- PEG- EPS next Q-0.23 Inst Own0.01% Short Float / Ratio0.04% / 0.02 Perf Quarter-38.51%
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.00M Perf Half Y-
Book/sh0.55 P/B6.92 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.40 P/C9.57 EPS next 5Y- ROE- 52W Range1.33 - 7.98 Perf YTD-48.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-52.38% Beta-
Dividend %- Quick Ratio6.99 Sales past 5Y0.00% Gross Margin- 52W Low185.71% ATR0.72
Employees- Current Ratio6.99 Sales Q/Q- Oper. Margin- RSI (14)58.10 Volatility20.39% 24.54%
OptionableNo Debt/Eq0.01 EPS Q/Q-48.08% Profit Margin- Rel Volume0.54 Prev Close3.55
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume177.51K Price3.80
Recom- SMA2042.93% SMA5019.49% SMA200-11.67% Volume95,409 Change7.04%
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Baltimore, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cappy George10% OwnerAug 07Buy7.00119,048833,3362,859,318Aug 24 05:38 PM
Cappy George10% OwnerAug 02Buy7.00157,1701,100,1902,740,270Aug 04 01:42 PM